Malignant Neoplasm Of Common Bile Duct Carcinoma — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for malignant neoplasm of common bile duct carcinoma . 15 active patents protecting 1 drugs from 1+ originators. First major cliff: 2034. Daily refresh.

1
Approved drugs
15
Active US patents
45/100
Avg vulnerability
$200M
Annual revenue covered

Originators in Malignant Neoplasm Of Common Bile Duct Carcinoma

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Incyte Corp 15 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating malignant neoplasm of common bile duct carcinoma . Each bar = one year. Y-axis scaled to peak year (6 patents).

3
34
3
35
3
39
6
40

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Pemazyre
PEMIGATINIB
 Incyte Corp 15 45 $200M 2034-04-17

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
11466004 Pemazyre method of use 70 2039-05-03
11466004 Pemazyre method of use 70 2039-05-03
11466004 Pemazyre method of use 70 2039-05-03
11628162 Pemazyre method of use 70 2040-08-30
11628162 Pemazyre method of use 70 2040-08-30
11628162 Pemazyre method of use 70 2040-08-30
10131667 Pemazyre method of use 62 2034-04-17
10131667 Pemazyre method of use 62 2034-04-17
10131667 Pemazyre method of use 62 2034-04-17
12552792 Pemazyre composition of matter 17 2040-10-03

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
9611267 Pemazyre composition of matter 4 2035-01-30
9611267 Pemazyre composition of matter 4 2035-01-30
9611267 Pemazyre composition of matter 4 2035-01-30
12552792 Pemazyre composition of matter 17 2040-10-03
12552792 Pemazyre composition of matter 17 2040-10-03
12552792 Pemazyre composition of matter 17 2040-10-03
10131667 Pemazyre method of use 62 2034-04-17
10131667 Pemazyre method of use 62 2034-04-17
10131667 Pemazyre method of use 62 2034-04-17
11628162 Pemazyre method of use 70 2040-08-30

Related